|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1939 USD | +4.27% |
|
-0.26% | -15.25% |
| 05-15 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-21 | Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic | CI |
Evolution of the Average Target: Northwest Biotherapeutics, Inc.
Evolution of the Target Price: Northwest Biotherapeutics, Inc.
Changes in Analyst Recommendations: Northwest Biotherapeutics, Inc.
1c73.A61SJTPuHXW2obDUh4WlmcgFvQNg_unHuWRC06vfutA.aeVrY2GhVB75ycCL173B95tU2HU5uKeRyxQ4sMqy-4pX1SNLSbpuHtjEww~20f365ce9243e36f136b8c735df85338
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +415.73% | |||
| +10.79% | |||||
| +23.51% | |||||
| +35.78% | |||||
| +90.61% | |||||
| +41.85% | |||||
| +35.91% | |||||
| -21.53% | |||||
| -9.62% | |||||
| +31.01% | |||||
| Average | +65.40% | |||||
| Weighted average by Cap. | +26.82% |
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1939USD
Average target price
1.000USD
Spread / Average Target
+415.73%
High Price Target
1.000USD
Spread / Highest target
+415.73%
Low Price Target
1.000USD
Spread / Lowest Target
+415.73%
Analyst Consensus Detail
Consensus revision (last 18 months)
SellBuy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1939USD
Average target price
1.000USD
Spread / Average Target
+415.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- NWBO Stock
- Consensus Northwest Biotherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
